The global gastrointestinal drugs market is witnessing strong growth due to the increasing prevalence of digestive disorders, rising healthcare awareness, expanding biologics development, and growing pharmaceutical innovations. Gastrointestinal drugs are widely used to treat disorders affecting the digestive tract, including irritable bowel syndrome (IBS), ulcerative colitis, Crohn’s...
Orthobiologics Market Advances Through Clinical Precision Era: Why Bone Graft Substitutes Are Becoming a Surgical Standard
NEWARK, DE / According to the latest market analysis by Future Market Insights, the orthobiologics market is entering a phase of steady, procedure-driven expansion, supported by rising orthopedic surgical volumes, aging patient populations, and increasing...
The global rare neurological disease treatment market is witnessing substantial growth due to increasing awareness regarding rare neurological disorders, rising investments in orphan drug development, and rapid advancements in biotechnology and precision medicine. Rare neurological diseases are complex disorders that affect the brain, spinal cord, nerves, and muscles, often leading to severe...
The evolution of biologics is reshaping how modern medicines are developed, produced, and delivered, and at the center of this transformation lies the growing importance of the large molecule CDMO ecosystem. As pharmaceutical companies increasingly focus on innovation while outsourcing complex manufacturing processes, the role of a reliable biologics CDMO has become more strategic than ever....
The global targeted oncology biologics market is poised for robust expansion, projected to grow from USD 74,751.0 million in 2026 to USD 186,948.7 million by 2036, registering a CAGR of 9.6% over the forecast period, according to Future Market Insights (FMI). This growth is driven by the structural shift in oncology care toward molecularly defined treatment pathways, where therapies...
U.S. Pharmaceutical CDMO Growth Driven by Biologics, Fill Finish, and Smart Manufacturing
The U.S. Pharmaceutical CDMO sector is becoming a strategic pillar of modern healthcare as drug developers seek faster launches, lower capital risk, and reliable domestic capacity. Contract development and manufacturing organizations now play a larger role in drug manufacturing, helping pharmaceutical and...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt